(Reuters) - "With the designation of priority review, we expect an action on the application from the FDA in August of this year and are thus moving forward with commercialisation plans for satraplatin," GPC said in a statement.
Read more at Reuters.com Government Filings News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment